口腔鳞状细胞癌患者术后服用二甲双胍对预后的影响

doi:10.19439/j.sjos.2021.01.012

上海口腔医学 ›› 2021, Vol. 30 ›› Issue (1): 61-65.doi: 10.19439/j.sjos.2021.01.012

口腔鳞状细胞癌患者术后服用二甲双胍对预后的影响

黄丹妮¹, 陈文鑫¹, 熊浩峰^1,2, 胡鑫¹, 毛婷¹, 苏彤¹

1.中南大学湘雅医院口腔医学中心,湖南长沙 410008;
2.中南大学生命科学学院医学遗传学研究中心,湖南长沙 410008

收稿日期:2019-08-15 修回日期:2020-01-06 出版日期:2021-02-25 发布日期:2021-04-02
通讯作者: 苏彤,E-mail: sutong@csu.edu.cn
作者简介:黄丹妮（1996-）,女,硕士,E-mail: 13755038722@163.com
基金资助:
国家自然科学基金（81873717）; 湖南省自然科学基金（2019JJ40508）

Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment

HUANG Dan-ni¹, CHEN Wen-xin¹, XIONG Hao-feng^1,2, HU Xin¹, MAO Ting¹, SU Tong¹

1. Centre of Stomatology, Xiangya Hospital, Central South University. Changsha 410008;
2. Center of Medical Genetics, School of Life Sciences, Central South University. Changsha 410008, Hunan Province, China

Received:2019-08-15 Revised:2020-01-06 Online:2021-02-25 Published:2021-04-02

摘要/Abstract

摘要： 目的:研究二甲双胍对口腔鳞状细胞癌（简称鳞癌）术后患者预后的影响。方法:选择2015年10月—2016年10月间中南大学湘雅医院收治的口腔鳞癌患者346例,分为实验组（71例）和对照组（275例）。实验组术后服用二甲双胍类药物,对照组术后未服用二甲双胍药物。比较2组患者的临床随访结果。采用SPSS 21.0 软件包对数据进行统计学分析。结果:与对照组相比,实验组患者复发率较低。在男性患者、原发于舌部的肿瘤患者、高分化鳞癌患者、有淋巴结转移的患者以及有咀嚼槟榔史的患者中,差异更加显著(P<0.05)。结论:口腔鳞癌患者术后口服二甲双胍,能在一定程度上降低术后复发率及转移率。

关键词: 口腔鳞状细胞癌, 复发, 转移, 二甲双胍

Abstract: PURPOSE: To investigate the effect of metformin on the prognosis of patients with oral squamous cell carcinoma after surgical treatment. METHODS: Three hundred and forty-six patients with oral squamous cell carcinoma after operation in Xiangya Hospital of Central South University from October 2015 to October 2016 were selected and divided into experimental group and control group. In the experimental group, 71 patients with oral squamous cell carcinoma received metformin after surgery. The control group included 275 patients without metformin after surgery of oral squamous cell carcinoma. The clinical follow-up results of patients in the two groups were compared. SPSS 21.0 software package was used to analyze the data. RESULTS: Compared with the control group, the recurrent rate of the experimental group was lower. The difference was more significant in male patients, patients with primary tongue tumor, patients with highly differentiated squamous cell carcinoma, patients with cervical lymph node metastasis, and patients with a history of chewing areca nut (P<0.05). CONCLUSIONS: Metformin can decrease postoperative recurrent rate and metastatic rate of oral squamous cell carcinoma after surgery.

Key words: Oral squamous cell carcinoma, Recurrence, Metastasis, Metformin

中图分类号:

R739.8

黄丹妮, 陈文鑫, 熊浩峰, 胡鑫, 毛婷, 苏彤. 口腔鳞状细胞癌患者术后服用二甲双胍对预后的影响[J]. 上海口腔医学, 2021, 30(1): 61-65.

HUANG Dan-ni, CHEN Wen-xin, XIONG Hao-feng, HU Xin, MAO Ting, SU Tong. Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment[J]. Shanghai Journal of Stomatology, 2021, 30(1): 61-65.

参考文献

[1] Fu JY, Gao J, Zhang ZY, et al.Tea consumption and the risk of oral cancer incidence: a case-control study from China[J]. Oral Oncol, 2013, 49(9): 918-922.
[2] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas[J]. Nature, 2015, 517(7536): 576-582.
[3] Chlebowski RT, Mctiernan A, Wactawski-Wende J, et al.Diabetes, metformin, and breast cancer in postmenopausal women[J]. J Clin Oncol, 2012, 30(23): 2844-2852.
[4] Kasper JS, Giovannucci E.A meta-analysis of diabetes mellitus and the risk of prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2056-2062.
[5] Garrett CR, Hassabo HM, Bhadkamkar NA, et al.Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer[J]. Br J Cancer, 2012, 106(8): 1374-1378.
[6] Mayer MJ, Klotz LH, Venkateswaran V.Metformin and prostate cancer stem cells: a novel therapeutic target[J]. Prostate Cancer Prostatic Dis, 2015, 18(4): 303-309.
[7] Lin H, Ying Y, Wang YY, et al.AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(12): 2369-2377.
[8] Tong D, Liu Q, Liu G, et al.Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis[J]. Cancer Lett, 2017, 389(1): 23-32.
[9] Cuyàs E, Fernández-Arroyo S, Buxó M, et al.Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients[J]. Aging (Albany NY), 2019, 11(9): 2874-2888.
[10] 林璐, 韩影, 熊浩峰, 等. 口腔鳞状细胞癌复发的临床和病理因素分析[J]. 北京医学, 2018, 40(10): 949-953.
[11] Bono F, De Smet F, Herbert C, et al.Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties[J]. Cancer Cell, 2013, 23(4): 477-488.
[12] Chen DS, Mellman I.Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330.
[13] Quinn BJ, Kitagawa H, Memmott RM, et al.Repositioning metformin for cancer prevention and treatment[J]. Trends Endocrinol Metab, 2013, 24(9): 469-480.
[14] Tseng CH.Metformin may reduce oral cancer risk in patients with type 2 diabetes[J]. Oncotarget, 2016, 7(2): 2000-2008.
[15] Evans JM, Donnelly LA, Emslie-Smith AM, et al.Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304-1305.
[16] Bowker SL, Majumdar SR, Veugelers P, et al.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin[J]. Diabetes Care, 2006, 29(2): 254-258.
[17] Jung Ys, Park CH, Eun CS, et al.Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32(5): 957-965.
[18] Mamtani R, Pfanzelter N, Haynes K, et al.Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas[J]. Diabetes Care, 2014, 37(7): 1910-1917.
[19] Bonanni B, Puntoni M, Cazzaniga M, et al.Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial[J]. J Clin Oncol, 2012, 30(21): 2593-2600.
[20] Sivalingam VN, Kitson S, Mcvey R, et al.Measuring the biological effect of presurgical metformin treatment in endometrial cancer[J]. Br J Cancer, 2016, 114(3): 281-289.
[21] Joshua AM, Zannella VE, Downes MR, et al.A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer[J]. Prostate Cancer Prostatic Dis, 2014, 17(3): 252-258.
[22] Curry J, Johnson J, Tassone P.Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial[J]. Laryngoscope, 2017, 127(8): 1808-1815.
[23] 郭峰, 翦新春, 周晌辉, 等. 口腔黏膜下纤维性变癌变的病理及临床生物学行为回顾性研究[J]. 中华口腔医学杂志, 2011, 46(8): 494-497.
[24] 母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2016年版)[J]. 中国糖尿病杂志, 2016, 24(10): 871-884.

口腔鳞状细胞癌患者术后服用二甲双胍对预后的影响

Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵娇, 隋佰延, 刘昕, 阮敏. 口腔鳞状细胞癌免疫相关预后风险模型的构建与验证[J]. 上海口腔医学, 2024, 33(4): 345-353.
[2]	郝妍, 白相宇, 霍峰, 陈喜波. 下调SETDB1通过SOX7甲基化抑制口腔癌上皮-间充质转化、侵袭和转移的机制探讨[J]. 上海口腔医学, 2024, 33(1): 30-35.
[3]	刘文静, 李梦琦, 崔祥, 汪俊兰. circ_0000326靶向miR-567对口腔鳞状细胞癌HSC3细胞增殖、侵袭及迁移的调控效应[J]. 上海口腔医学, 2023, 32(6): 590-596.
[4]	陈兴金, 范然怡, 陶识丞, 薛睿, 文旭涛, 麦华明. 颈淋巴清扫术保留胸锁乳突肌与否对晚期口腔鳞癌预后的影响[J]. 上海口腔医学, 2023, 32(6): 609-614.
[5]	裴婧, 张林, 贾云香, 陈蔚华. BRAF V600E在成釉细胞瘤、成釉细胞癌和囊肿中的表达[J]. 上海口腔医学, 2023, 32(6): 630-634.
[6]	叶婷婷, 陈蔚华, 裴婧, 贾云香, 吴海莹. NEK2与EMT相关分子在口腔鳞状细胞癌中的表达及临床意义[J]. 上海口腔医学, 2023, 32(6): 640-644.
[7]	刘珂, 艾合买提·艾尼娃, 图尔妮萨古丽·克比尔, 古丽努尔·阿吾提. 二甲双胍联合DPP-4抑制剂对2型糖尿病伴慢性牙周炎患者牙槽骨密度的影响[J]. 上海口腔医学, 2023, 32(4): 410-416.
[8]	叶璞, 黄兴鸿, 张伟, 吴萌, 俞辉明. cN0期舌鳞癌患者颈淋巴结转移的相关因素及预后分析[J]. 上海口腔医学, 2022, 31(5): 540-543.
[9]	陈娟, 曹若妍, 刘洋, 洪鹏宇, 唐瞻贵. TNFAIP6在口腔疣状癌与口腔鳞状细胞癌中的表达及其与临床病理的关系[J]. 上海口腔医学, 2022, 31(2): 167-172.
[10]	罗号, 袁壮, 吴开柳, 贺捷, 孟箭. 92例上颌骨成釉细胞瘤不同手术方式的效果评价[J]. 上海口腔医学, 2022, 31(1): 71-74.
[11]	徐万林, 朱云, 卢浩, 丁继平, 姚原, 刘胜文, 张陈平, 杨雯君. 腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告[J]. 上海口腔医学, 2021, 30(6): 667-672.
[12]	高远, 陈杰, 王高琦, 李云凯, 卞翠荣. 种植体-基台连接设计对基台与基台螺丝受力影响的三维有限元分析[J]. 上海口腔医学, 2021, 30(5): 481-487.
[13]	靳能皓, 南欣荣, 闫星泉. BTG1在78例口腔鳞癌中的表达及临床意义[J]. 上海口腔医学, 2021, 30(2): 140-144.
[14]	代书林, 王旭霞, 乜福娇, 崔群, 韩媛媛, 张君. 异普黄酮对大鼠正畸牙复发过程中牙周组织改建的影响[J]. 上海口腔医学, 2021, 30(1): 23-27.
[15]	王科, 彭国光, 谭玉莲, 何善志, 罗翠芬. miR-99a对口腔鳞癌增殖能力的影响[J]. 上海口腔医学, 2021, 30(1): 44-49.